{
    "clinical_study": {
        "@rank": "42074", 
        "brief_summary": {
            "textblock": "To evaluate the safety and antiretroviral activity of saquinavir soft gelatin capsule\n      formulation (SQV-SGC) in combination with other antiretroviral drugs."
        }, 
        "brief_title": "The Safety and Effectiveness of Saquinavir Soft Gelatin Capsules Combined With Other Anti-HIV Drugs", 
        "condition": "HIV Infections", 
        "condition_browse": {
            "mesh_term": [
                "HIV Infections", 
                "Acquired Immunodeficiency Syndrome"
            ]
        }, 
        "detailed_description": {
            "textblock": "All patients receive SQV as monotherapy or in combination with other antiretroviral drugs\n      chosen by the investigator and patient. (This study provides only SQV.) Patients may not\n      choose another protease inhibitor (PI) as part of their combination therapy; furthermore,\n      patients taking PIs other than SQV must undergo a 5-day washout period before study-drug\n      administration. Patients are monitored for adverse events and changes in routine laboratory\n      tests, plasma viral load, and CD4+ T cell levels. Outcomes are analyzed by stratifying\n      patients according to CD4+ T cell levels and prior history with protease inhibitors."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria\n\n        Concurrent Medication:\n\n        Allowed:\n\n        Antiretroviral treatments other than PIs.\n\n        Patients must have:\n\n          -  HIV infection.\n\n          -  No prior experience with PIs. (Note:\n\n          -  At least 75 percent of patients must be naive to PIs.)\n\n        Exclusion Criteria\n\n        Concurrent Medication:\n\n        Excluded:\n\n        PIs other than SQV.\n\n        Prior Medication:\n\n        Excluded:\n\n        Any PIs (see note in General Criteria--Inclusion)."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "13 Years"
        }, 
        "enrollment": "400", 
        "firstreceived_date": "November 2, 1999", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT00002425", 
            "org_study_id": "229E", 
            "secondary_id": "NV15182B"
        }, 
        "intervention": {
            "intervention_name": "Saquinavir", 
            "intervention_type": "Drug"
        }, 
        "intervention_browse": {
            "mesh_term": [
                "HIV Protease Inhibitors", 
                "Saquinavir", 
                "Anti-HIV Agents"
            ]
        }, 
        "keyword": [
            "Drug Therapy, Combination", 
            "Saquinavir", 
            "HIV Protease Inhibitors", 
            "Dosage Forms", 
            "Anti-HIV Agents"
        ], 
        "lastchanged_date": "June 23, 2005", 
        "location": {
            "facility": {
                "address": {
                    "city": "Nutley", 
                    "country": "United States", 
                    "state": "New Jersey", 
                    "zip": "071101199"
                }, 
                "name": "Consumer Contact"
            }
        }, 
        "location_countries": {
            "country": "United States"
        }, 
        "official_title": "A Multicenter, Open-Label Study of the Safety and Activity of Saquinavir Soft Gelatin Capsule Formulation (Saquinavir SGC) in Combination With Other Antiretroviral Drugs", 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration"
        }, 
        "phase": "Phase 4", 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT00002425"
        }, 
        "source": "NIH AIDS Clinical Trials Information Service", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Hoffmann-La Roche", 
                "agency_class": "Industry"
            }
        }, 
        "study_design": "Endpoint Classification: Safety Study, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "December 1996"
    }, 
    "geocoordinates": {
        "Consumer Contact": "40.822 -74.16"
    }
}